Streetbeat News

Revenues

RVTY

Revvity shares are trading higher following the announcement of their preliminary Q4 revenue guidance, indicating a positive outlook for the company's financial performance.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 3:22 pm

MRK

Merck & Co (NYSE:MRK) has received mixed analyst ratings over the past quarter, with 9 analysts offering opinions ranging from bullish to indifferent. The average 12-month price target for MRK is $130.56, reflecting an 8.8% increase from the previous target of $120.00. Analysts from firms including Cantor Fitzgerald, TD Cowen, Deutsche Bank, Morgan Stanley, and BMO Capital have provided ratings and adjusted price targets, with the highest target being $135.00 and the lowest at $115.00. Merck's financial performance shows strong market presence, revenue growth, and financial health, with a market capitalization above industry average, a positive revenue trend, high net margin, ROE, and ROA, and a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 3:01 pm

AEO

Analysts have updated their ratings and price targets for American Eagle Outfitters (NYSE:AEO), with an average 12-month price target of $18.57, up from $15.70. The company has shown positive revenue growth, a high net margin, and strong ROE and ROA, with a lower than average debt-to-equity ratio. The majority of analysts are currently indifferent, with one somewhat bearish, reflecting a cautious outlook.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 3:01 pm

APLS

Apellis Pharmaceuticals (NASDAQ:APLS) has received 12 analyst ratings in the last three months, with a mix of bullish and bearish sentiments. The average 12-month price target is $67.67, down from the previous $69.40. Analysts from firms like Goldman Sachs, Citigroup, and others have adjusted their price targets and ratings, reflecting their latest views on the company's performance. Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on the complement system. Despite a significant revenue growth rate of 400.54% as of September 30, 2023, the company's net margin and ROE are below industry averages, and it has a prudent debt-to-equity ratio of 0.47.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 3:00 pm

JXN

Four analysts have maintained a neutral stance on Jackson Financial Inc (NYSE:JXN) over the past three months, with no change in sentiment. The average 12-month price target for JXN has been raised to $43.75, up from $36.00, with a high estimate of $55.00 and a low of $35.00. Analysts from Goldman Sachs and Morgan Stanley have raised their price targets, while Jefferies has announced a hold rating with a target of $55.00. Despite a revenue decline of -12.1% as of September 30, 2023, JXN has a high net margin of 105.66% and an ROE of 32.37%, indicating strong profitability and financial performance.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 3:00 pm

ACCD

Accolade Inc (NASDAQ:ACCD) shares surged after reporting Q3 FY24 results with a 9% revenue increase to $99.4 million, surpassing estimates. Adjusted gross profit rose 10% Y/Y, and adjusted EBITDA loss narrowed significantly. The EPS loss was also less than expected. The company raised its FY24 revenue guidance and expects continued growth into FY25. Wedbush analyst Ryan Daniels reaffirmed an Outperform rating, citing strong sales momentum and visibility into FY25.

Portfolio Pulse from Lekha Gupta

January 09, 2024 | 2:51 pm

BETS

EFTR

GRFS

GRTX

MCRB

SNTG

U.S. stock markets opened lower with the Dow Jones dropping over 200 points. Health care shares saw a marginal increase, while real estate shares declined by 1.2%. The U.S. trade deficit narrowed to $63.2 billion in November, less than market expectations. Sentage Holdings, Galera Therapeutics, and Seres Therapeutics experienced significant stock price increases, while Grifols, eFFECTOR Therapeutics, and Bit Brother saw their shares fall sharply.

Portfolio Pulse from Avi Kapoor

January 09, 2024 | 2:40 pm

URBN

Urban Outfitters reported a 10% increase in total company net sales for the two months ended December 31, 2023, leading to a rise in its stock price.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:37 pm

BTCUSD

El Salvador's sovereign bonds, particularly the one due in June 2035, have surged over 200% following the country's Bitcoin investments turning profitable. Bitcoin's value doubled, coinciding with the bond rally and the anticipated approval of a Bitcoin ETF. El Salvador's economy grew by 3.6% in Q3 2023, and its Bitcoin portfolio has seen a 10.2% increase in profits. Despite IMF warnings about the risks of Bitcoin as legal tender and Bitcoin-backed bonds, El Salvador's financial strategy appears successful for now.

Portfolio Pulse from Piero Cingari

January 09, 2024 | 2:24 pm

NBY

SNOA

NovaBay Pharmaceuticals and Sonoma Pharmaceuticals have reached an agreement to market Avenova-branded products in the European Union. Under the agreement, Sonoma will manufacture the eye product Ocudox and pay NovaBay a royalty fee based on net product sales. The products will be marketed through Sonoma's European distribution network, leveraging NovaBay's Avenova brand and Sonoma's distribution expertise.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 2:18 pm